W
WAVEMAN · COMPANY
ALGN · Align Technology Inc
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

ALGN

ALIGN TECHNOLOGY INC
MEDICAL DEVICES · ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES · CIK 0001097149
SEC FILINGS☆ WATCH
INSIDER NET · 180D
-
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
300
13F, latest reported quarter
REVENUE GROWTH
+0.9%
XBRL, annual
NET MARGIN
10.2%
CONVERSIONS · 180D
10
codes C/M, not in net · $0 priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
no Form 4 purchases or sales on file
CONGRESS
no member of Congress has reported trading it
FUNDS
300 funds added or opened last quarter
more than 83% of Medical Devices
REVENUE
+0.9% year over year
below 71% of Medical Devices
MARGIN
10.2% net margin
more than 77% of Medical Devices
BUYBACKS
$98.1M repurchased, FY to 2026-06-30
more than 59% of Medical Devices
SHORT
5.9% of shares outstanding short · 4.0 days to cover · settled 2026-07-31
more than 71% of Medical Devices
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
300 funds added or opened positions in the latest 13F quarter, of 678 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +15.7%
+15.7%12M
-9%+9%+26%+44%2025-092025-102025-122026-032026-052026-072026-09 2026-02-18 · Morici John sold $1.5M
INSIDER SELL
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
The complete filing record, in one place.
The record shows 300 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for ALIGN TECHNOLOGY INC in the period covered. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Morici John
EVP, CHIEF FINANCIAL OFFICER
SELL
2026-02-18
7,969.0
$1.5M
HOGAN JOSEPH M
PRESIDENT AND CEO
BUY
2025-08-01
7,576.0
$996.2K
Coletti Julie Ann
EVP, CHIEF LEGAL & REGULATORY
BUY
2025-07-31
42.0
$4.6K
LARKIN C RAYMOND JR
Director
BUY
2024-08-15
6,500.0
$1.5M
LACOB JOSEPH
Director
SELL
2024-02-29
800.0
$243.8K
65 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 60 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
BlackRock, Inc.
4,419,366.0 sh
$745.4M
VANGUARD CAPITAL MANAGEMENT LLC
4,401,313.0 sh
$742.3M
FMR LLC
4,060,032.0 sh
$684.8M
Capital International Investors
4,045,561.0 sh
$682.3M
Capital World Investors
3,422,385.0 sh
$577.2M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Simplify Health Care ETF
$18.5M POSITION · AS OF 2026-03-31
7.9%
DAVENPORT EQUITY OPPORTUNITIES FUND
$31.4M POSITION · AS OF 2026-03-31
4.2%
Virtus KAR Mid-Cap ETF
$1.5M POSITION · AS OF 2026-04-30
3.5%
Virtus KAR Health Sciences Fund
$2.8M POSITION · AS OF 2026-03-31
3.1%
Virtus KAR Mid-Cap Core Fund
$56.0M POSITION · AS OF 2026-03-31
2.9%
Clarkston Fund
$2.6M POSITION · AS OF 2026-03-31
2.6%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 3 registered trials, 2 still enrolling or running — a status change here is dated weeks before the press release
3
Not applicable
2 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Executive pay vs shareholder return · Joseph Hogan
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2025
$19.2M
$3.9M
$4.3M
-71%
+17%
2024
$27.3M
$5.2M
$4.8M
-61%
+10%
2023
$29.0M
$29.5M
$4.4M
-49%
+0%
2022
$18.7M
-$61.3M
$3.4M
-61%
-7%
2021
$21.6M
$76.2M
$4.3M
+23%
+19%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$4.0B$4.0B$3.9B$3.7B
GROSS PROFIT$2.7B$2.8B$2.7B$2.6B
OPERATING INCOME$545.8M$607.6M$643.3M$642.6M
NET INCOME$410.0M$421.0M$445.0M$362.0M
EPS (DILUTED)5.655.625.814.61
OPERATING CASH FLOW$593.2M$738.2M$785.8M$568.7M
CASH$1.1B$1.0B$937.4M$942.0M
BUYBACKS$465.9M$352.9M$592.4M$435.0M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →